Skip to main content
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1983 Sep;16(3):333–335. doi: 10.1111/j.1365-2125.1983.tb02170.x

Blood monocyte aryl hydrocarbon hydroxylase activity in psoriasis.

G Mason, M D Rawlins, S Shuster
PMCID: PMC1428007  PMID: 6313027

Abstract

The activity of aryl hydrocarbon hydroxylase (AHH) in monocytes from 13 healthy control subjects and in 16 patients with discoid psoriasis was measured. The mean basal monocyte AHH activities of the control and psoriatic groups were 3.4 +/- 0.47 and 4.46 +/- 0.55 respectively (pmol 3-OHBP h-1 10(-6) cells). This difference was not significant. The mean induced monocyte AHH activities in the control and psoriatic groups were 56.4 +/- 10.8 and 77.8 +/- 16.0 pmol 3-OHBP h-1 10(-6) cells respectively but this difference was not significant. The mean induction ratios in the control and psoriatic groups were 16.5 +/- 1.8 and 20.4 +/- 3.6 respectively. Again, this difference was not significant. We conclude therefore, that monocyte aryl hydrocarbon hydroxylase activity is not reduced in psoriasis.

Full text

PDF
333

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bast R. C., Jr, Okuda T., Plotkin E., Tarone R., Rapp H. J., Gelboin H. V. Development of an assay for aryl hydrocarbon (benzo(a)pyrene) hydroxylase in human peripheral blood monocytes. Cancer Res. 1976 Jun;36(6):1967–1974. [PubMed] [Google Scholar]
  2. Brewer C., Smith W. J. The dangerous alcoholic. Lancet. 1982 Jul 31;2(8292):271–271. doi: 10.1016/s0140-6736(82)90352-x. [DOI] [PubMed] [Google Scholar]
  3. Chapman P. H., Kersey P. J., Keys B., Shuster S., Rawlins M. D. Generalised tissue abnormality of aryl hydrocarbon hydroxylase in psoriasis. Br Med J. 1980 Nov 15;281(6251):1315–1316. doi: 10.1136/bmj.281.6251.1315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chapman P. H., Rawlins M. D., Shuster S. Activity of aryl hydrocarbon hydroxylase in psoriatic skin. Lancet. 1979 Feb 10;1(8111):297–298. doi: 10.1016/s0140-6736(79)90706-2. [DOI] [PubMed] [Google Scholar]
  5. Finnen M. J., Shuster S., Lawrence C. M., Rawlins M. D. Aryl hydrocarbon hydroxylase activity and psoriasis. Biochem Pharmacol. 1983 Jun 1;32(11):1707–1711. doi: 10.1016/0006-2952(83)90113-2. [DOI] [PubMed] [Google Scholar]
  6. Kellermann G., Luyten-Kellermann M., Shaw C. R. Genetic variation of aryl hydrocarbon hydroxylase in human lymphocytes. Am J Hum Genet. 1973 May;25(3):327–331. [PMC free article] [PubMed] [Google Scholar]
  7. Kärki N. T., Karvonen J., Pelkonen O. Aryl hydrocarbon hydroxylase activity in cultured lymphocytes of psoriatic patients. Arch Dermatol Res. 1982;273(1-2):103–109. doi: 10.1007/BF00509033. [DOI] [PubMed] [Google Scholar]
  8. Nebert D. W., Gelboin H. V. Substrate-inducible microsomal aryl hydroxylase in mammalian cell culture. I. Assay and properties of induced enzyme. J Biol Chem. 1968 Dec 10;243(23):6242–6249. [PubMed] [Google Scholar]
  9. Ruzicka T., Vizethum W., Jacobs A., Goerz G. Arylhydrocarbon hydroxylase activity in lymphocytes of patients with psoriasis. Lancet. 1980 May 24;1(8178):1142–1143. doi: 10.1016/s0140-6736(80)91596-2. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES